 |
YANTAI, China, Dec. 18, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, has recently confirmed that under the 2023 simple renewal mechanism of China National Healthcare Security Administration (NHSA), on January 1, 2024, the updated National Reimbursement Drug List (NRDL) will continue to include Telitacicept (RC18) and Disitamab Vedotin (RC48) for the next two-year agreement. This achievement represents a significant milestone for RemeGen in the innovative pharmaceutical industry and reinforces its prominent position in the market. The successful renewal also underscores the effectiveness of RemeGen's business strategy and highlights positive strides in enhancing the accessibility of innovative drugs within the Chinese market.
"The simplified renewal provides a solid foundation for the sustainable development of innovative drug companies such as RemeGen and allows for the continuous improvement of patient access to innovative drugs, meaning patients can truly benefit from healthcare innovations." said Dr. Jianmin Fang, CEO of RemeGen.
Telitacicept, RemeGen's proprietary novel fusion protein for the treatment of autoimmune diseases and the world's first innovative dual-target biological agent for treating systemic lupus erythematosus (SLE), received approval from China's National Medical Products Administration (NMPA) in March 2021 and subsequently entered the market. By December of the same year, the product was first added to the updated National Reimbursement Drug List (NRDL) to treat adult patients with SLE. Upon conditional marketing approval from the NMPA on March 9, 2021, it received full marketing approval on November 22 this year. The results of the Phase III study of Telitacicept showed the SRI-4 Telitacicept group response rate to be significantly higher than that of the placebo group (82.6% vs 38.1%), with positive effects.
Disitamab Vedotin, an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid cancers with significant unmet medical needs, obtained marketing approval in June and December 2021, respectively, for treating patients with HER2-expressing locally advanced or metastatic gastric cancer (GC) and advanced urothelial cancer (mUC). In December 2021, the HER2-expressing GC indication was successfully included in the updated NRDL. Furthermore, in January 2023, related urothelial cancer indication was also added to the same NRDL.
As per the information presented in RemeGen's 2022 annual report, the inclusion of Telitacicept and Disitamab Vedotin on the NRDL at the close of 2021 had a substantial impact on product production and sales in 2022. Notably, sales witnessed a remarkable surge, escalating by 1780 percent and 1513 percent for Telitacicept and Disitamab Vedotin, respectively, compared to the preceding year. This not only underscores the effectiveness and growing popularity of these drugs among patients but also signifies a substantial rise in drug demand, attributed to the alleviation of financial burdens on patients through medical insurance.
The successful renewal by RemeGen not only showcases its robust competitiveness in the Chinese market but also mirrors the rapid development of medical care in China while serving as a positive example of China's pharmaceutical industry on the global stage. Looking ahead, RemeGen is poised to maintain a pivotal role in the global pharmaceutical market.
About RemeGen Co. Ltd.
Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices throughout China and the United States. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases. For more details, please visit: www.remegen.com
About Telitacicept (RC18)
Telitacicept (RC18) is RemeGen's proprietary novel fusion protein for the treatments of autoimmune diseases. It is constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor and the fragment crystallizable (Fc) domain of human immunoglobulin G(IgG). Telitacicept targets two cell-signaling molecules critical for B-lymphocyte development: B-lymphocyte stimulator(BLyS) and a proliferation-inducing ligand (APRIL), which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in several autoimmune diseases. It was granted conditional marketing approval by China's National Medical Products Administration (NMPA) to treat systemic lupus erythematosus (SLE) in March 2021.
About Disitamab Vedotin (RC48)
Disitamab Vedotin (RC48) is an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid cancers with significant unmet medical needs and is the first domestically developed ADC to receive marketing approval in China. The drug was granted conditional marketing approval in June 2021 by the National Medical Products Administration (NMPA) in China to treat locally advanced or metastatic gastric cancer. In the same month, the company submitted an Investigational New Drug (IND) application for the treatment of HER2-expressing advanced or metastatic urothelial carcinoma with disitamab vedotin. In 2021, RemeGen and Seagen Inc. entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin.
The company is implementing a differentiated development and commercial strategy for disitamab vedotin, including (i) gastric cancer (GC), (ii) urothelial carcinoma (UC), (iii) breast cancer (BC), and (iv) other HER2-expressing cancers.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to RemeGen, are intended to identify certain of such forward-looking statements. RemeGen does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of RemeGen with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond RemeGen's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, RemeGen's competitive environment and political, economic, legal and social conditions.
RemeGen, the Directors and the employees of RemeGen assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements do not materialize or turn out to be incorrect.
